Paul B Manning
CIK 1494695 · last filed 2026-07-01
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$166.72M
Companies
7
Total Filings
77
Lifetime Open-Market Net
$75.20M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CADL | Director | 2,984,752 | $10.65 | $31.79M | $23.91M | 13 | 2026-07-01 |
| LQDA | Director | 911,139 | $88.05 | $80.23M | -$24.24M | 16 | 2026-06-18 |
| VRCA | Director | 7,306,561 | $5.22 | $38.14M | $48.04M | 17 | 2025-11-25 |
| TSHA | Director | 1,355,333 | $6.68 | $9.05M | $25.15M | 13 | 2025-06-03 |
| ABOS | 10%+ Owner | 3,040,193 | $2.47 | $7.51M | $5.00M | 1 | 2021-07-08 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $7.34M | 8 | 2019-11-12 |
| AveXis, Inc. (AVXS) Delisted | Director | 0 | — | — | -$10.00M | 6 | 2018-05-15 |
Recent Filings · Page 6 of 8
77 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-19 | LQDA | Grant (A) | — | $0 | EDGAR |
| 2020-09-30 | TSHA | Conv (C) | +5,295,307 | $0 | EDGAR |
| 2020-09-25 | TSHA | Grant (A) | — | $0 | EDGAR |
| 2020-08-21 | VRCA | Buy (P) | +20,000 | $181.8K | EDGAR |
| 2020-08-19 | VRCA | Buy (P) | +10,000 | $85.5K | EDGAR |
| 2020-08-18 | VRCA | Buy (P) | +6,000 | $41.5K | EDGAR |
| 2020-08-17 | VRCA | Buy (P) | +158,500 | $1.02M | EDGAR |
| 2019-11-12 | Dova Pharmaceuticals Inc. (DOVA) Delisted | U | −14,762,242 | -$405.96M | EDGAR |
| 2019-10-10 | VRCA | Buy (P) | +20,886 | $300.3K | EDGAR |
| 2019-08-12 | Dova Pharmaceuticals Inc. (DOVA) Delisted | Buy (P) | +28,062 | $445.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.